Literature DB >> 21761135

Biobanking and international interoperability: samples.

Michael Kiehntopf1, Michael Krawczak.   

Abstract

In terms of sample exchange, international collaborations between biobanks, or between biobanks and their research partners, have two important aspects. First, the donors' consent usually implies that the scope and purpose of any sample transfer to third parties is subject to major constraints. Since the legal, ethical and political framework of biobanking may differ substantially, even between countries of comparable jurisdictional systems, general rules for the international sharing of biomaterial are difficult, if not impossible, to define. Issues of uncertainty include the right to transfer the material, the scope of research allowed, and intellectual property rights. Since suitable means of international law enforcement may not be available in the context of biobanking, collaborators are advised to clarify any residual uncertainty by means of bilateral contracts, for example, in the form of material transfer agreements. Second, biobank partners may rightly expect that the biomaterial they receive for further analysis attains a certain level of quality. This implies that a biobank has to implement stringent quality control measures covering, in addition to the material transfer itself, the whole process of material acquisition, transport, pre-analytical handling and storage. Again, it may be advisable for biobank partners to claim contractual warranties for the type and quality of the biomaterial they wish to acquire.

Mesh:

Year:  2011        PMID: 21761135     DOI: 10.1007/s00439-011-1068-8

Source DB:  PubMed          Journal:  Hum Genet        ISSN: 0340-6717            Impact factor:   4.132


  30 in total

Review 1.  International efforts to develop biospecimen best practices.

Authors:  Jimmie B Vaught; Elodie Caboux; Pierre Hainaut
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-03-16       Impact factor: 4.254

2.  Characterization of differences between blood sample matrices in untargeted metabolomics.

Authors:  Judith R Denery; Ashlee A K Nunes; Tobin J Dickerson
Journal:  Anal Chem       Date:  2010-12-22       Impact factor: 6.986

3.  Analytical and preanalytical biases in serum proteomic pattern analysis for breast cancer diagnosis.

Authors:  Aly Karsan; Bernhard J Eigl; Stephane Flibotte; Karen Gelmon; Philip Switzer; Patricia Hassell; Dorothy Harrison; Jennifer Law; Malcolm Hayes; Moira Stillwell; Zhen Xiao; Thomas P Conrads; Timothy Veenstra
Journal:  Clin Chem       Date:  2005-06-10       Impact factor: 8.327

4.  Assay interferences from blood collection tubes: a cautionary note.

Authors:  Ana K Stankovic; Girish Parmar
Journal:  Clin Chem       Date:  2006-08       Impact factor: 8.327

5.  Systematical evaluation of the effects of sample collection procedures on low-molecular-weight serum/plasma proteome profiling.

Authors:  Sen-Yung Hsieh; Ren-Kung Chen; Yi-Hsin Pan; Hai-Lun Lee
Journal:  Proteomics       Date:  2006-05       Impact factor: 3.984

6.  Long-term stability of coagulation variables: Protein S as a biomarker for preanalytical storage-related variations in human plasma.

Authors:  Fotini Betsou; Bertrand Roussel; Nicolas Guillaume; Jean-Jacques Lefrère
Journal:  Thromb Haemost       Date:  2009-06       Impact factor: 5.249

7.  Progressive degradation of serum samples limits proteomic biomarker discovery.

Authors:  Shadab Ahmad; Elayanambi Sundaramoorthy; Reena Arora; Somdutta Sen; Ganesan Karthikeyan; Shantanu Sengupta
Journal:  Anal Biochem       Date:  2009-07-24       Impact factor: 3.365

8.  Banking together. A unified model of informed consent for biobanking.

Authors:  Elena Salvaterra; Lucilla Lecchi; Silvia Giovanelli; Barbara Butti; Maria Teresa Bardella; Pier Alberto Bertazzi; Silvano Bosari; Guido Coggi; Domenico A Coviello; Faustina Lalatta; Maurizio Moggio; Mario Nosotti; Alberto Zanella; Paolo Rebulla
Journal:  EMBO Rep       Date:  2008-04       Impact factor: 8.807

9.  Investigation of peptide biomarker stability in plasma samples using time-course MS analysis.

Authors:  Jizu Yi; Zhaoxia Liu; Craig A Gelfand; David Craft
Journal:  Methods Mol Biol       Date:  2011

Review 10.  TuBaFrost: European virtual tumor tissue banking.

Authors:  P H J Riegman; M H A Oomen; W N M Dinjens; J W Oosterhuis; K H Lam; A Spatz; C Ratcliffe; K Knox; R Mager; D Kerr; F Pezzella; B Van Damme; M Van De Vijver; H Van Boven; M M Morente; S Alonso; D Kerjaschki; J Pammer; J A López-Guerrero; A Llombart-Bosch; A Carbone; A Gloghini; I Teodorovic; M Isabelle; A Passioukov; S Lejeune; P Therasse; E B Van Veen
Journal:  Adv Exp Med Biol       Date:  2006       Impact factor: 2.622

View more
  13 in total

1.  Sustainability in Biobanking.

Authors:  Maram Abdaljaleel; Elyse J Singer; William H Yong
Journal:  Methods Mol Biol       Date:  2019

2.  The art and science of biobanking.

Authors:  Bartha Maria Knoppers; Thomas J Hudson
Journal:  Hum Genet       Date:  2011-07-21       Impact factor: 4.132

Review 3.  [Preanalytics and biobanking : Influence of preanalytical factors on tissue sample quality].

Authors:  K-F Becker; J Wipperfürth; E Herpel
Journal:  Pathologe       Date:  2018-07       Impact factor: 1.011

4.  Bridging consent: from toll bridges to lift bridges?

Authors:  Isabelle Budin-Ljøsne; Anne Marie Tassé; Bartha Maria Knoppers; Jennifer R Harris
Journal:  BMC Med Genomics       Date:  2011-10-04       Impact factor: 3.063

Review 5.  A critical analysis of cancer biobank practices in relation to biospecimen quality.

Authors:  Amanda Rush; Kevin Spring; Jennifer A Byrne
Journal:  Biophys Rev       Date:  2015-10-22

6.  How to build an integrated biobank: the Washington University Translational Cardiovascular Biobank & Repository experience.

Authors:  Kathryn A Yamada; Akshar Y Patel; Gregory A Ewald; Donna S Whitehead; Michael K Pasque; Scott C Silvestry; Deborah L Janks; Douglas L Mann; Jeanne M Nerbonne
Journal:  Clin Transl Sci       Date:  2013-04-18       Impact factor: 4.689

7.  Consent for use of clinical leftover biosample: a survey among Chinese patients and the general public.

Authors:  Yi Ma; HuiLi Dai; LiMin Wang; LiJun Zhu; HanBing Zou; XianMing Kong
Journal:  PLoS One       Date:  2012-04-27       Impact factor: 3.240

Review 8.  Regulations and Norms for Reuse of Residual Clinical Biospecimens and Health Data.

Authors:  Elizabeth E Umberfield; Sharon L R Kardia; Yun Jiang; Andrea K Thomer; Marcelline R Harris
Journal:  West J Nurs Res       Date:  2021-07-08       Impact factor: 1.774

9.  Legal & ethical compliance when sharing biospecimen.

Authors:  Tomas Klingstrom; Erik Bongcam-Rudloff; Jane Reichel
Journal:  Brief Funct Genomics       Date:  2018-01-01       Impact factor: 4.241

10.  Biobanks in the Era of Digital Medicine.

Authors:  Gunnar Jacobs; Andreas Wolf; Michael Krawczak; Wolfgang Lieb
Journal:  Clin Pharmacol Ther       Date:  2017-12-29       Impact factor: 6.875

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.